Terms: = Ovarian cancer AND NUP214, ENSG00000126883, 8021, MGC104525, D9S46E, RP11-544A12_7, N214, CAIN, P35658, CAN AND Clinical Outcome
209 results:
1. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With ovarian cancer.
Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
[TBL] [Abstract] [Full Text] [Related]
2. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
Neyrand S; Trecourt A; Lopez J; Just PA; Descotes F; Borson-Chazot F; Ray-Coquard I; Decaussin-Petrucci M; Devouassoux-Shisheboran M
Histopathology; 2024 Jan; 84(2):291-300. PubMed ID: 37771077
[TBL] [Abstract] [Full Text] [Related]
3. FOXL2 Mutation Status in Sex Cord-stromal Tumors Cannot be Predicted by Morphology.
Wessman S; Fuentes BB; Severin-Karlsson J; Westbom-Fremer S; Nistér M; Kokaraki G; Petta TB; Haglund F; Carlson JW
Int J Gynecol Pathol; 2024 Jan; 43(1):78-89. PubMed ID: 37255476
[TBL] [Abstract] [Full Text] [Related]
4. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.
McHenry A; Rottmann DA; Buza N; Hui P
Virchows Arch; 2023 Jul; 483(1):71-79. PubMed ID: 37219599
[TBL] [Abstract] [Full Text] [Related]
5. Lymph-vascular Space Involvement and/or p53 Overexpression Correlated With the clinical outcome of Early-stage Endometrial cancer Patients Treated With Adjuvant Vaginal Brachytherapy.
Laliscia C; Gadducci A; Coccia N; Mattioni R; Fuentes T; Caretto M; Pistolesi S; Puccini P; Perrone F; Morganti R; Paiar F
Anticancer Res; 2023 Jan; 43(1):149-156. PubMed ID: 36585177
[TBL] [Abstract] [Full Text] [Related]
6. Is microcystic, elongated, and fragmented pattern of myometrial invasion in endometrioid endometrial carcinoma associated with survival?
Altındağ SD; Yiğit S; Şen S
Turk J Med Sci; 2022 Oct; 52(5):1569-1579. PubMed ID: 36422476
[TBL] [Abstract] [Full Text] [Related]
7. clinical outcome of pulmonary lymphangitic carcinomatosis in gynecologic malignancy: A single-institution experience.
Kim MS; Jeong SY; Lee YY; Choi CH; Kim TJ; Kim BG; Bae DS; Lee JW
Taiwan J Obstet Gynecol; 2022 Mar; 61(2):333-338. PubMed ID: 35361397
[TBL] [Abstract] [Full Text] [Related]
8. Surgery due to mechanical bowel obstruction in relapsed ovarian cancer: clinical and surgical results of a bicentric analysis of 87 patients.
Armbrust R; Chekerov R; Sander S; Biebl M; Chopra S; Krell J; Rinne N; Nixon K; Fotopoulou C; Sehouli J
Arch Gynecol Obstet; 2022 Apr; 305(4):963-968. PubMed ID: 34596738
[TBL] [Abstract] [Full Text] [Related]
9. A Way to Reduce the Occurrence of Intraoperative Capsule Rupture in Presumed clinically Early-stage ovarian cancer with Adhesions to the Abdominal Wall.
Li J; Duan J; Mao R; Jiang W
J Minim Invasive Gynecol; 2022 Jan; 29(1):16. PubMed ID: 34265440
[TBL] [Abstract] [Full Text] [Related]
10. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
[TBL] [Abstract] [Full Text] [Related]
11. Significance of ERCC1 and Hormonal Receptor Expression in ovarian cancer.
El-Moniem Elrawi DA; El Khodary AI; Nassar HR; Darwish AD; Khorshed EN
J Med Invest; 2020; 67(3.4):391-398. PubMed ID: 33148925
[TBL] [Abstract] [Full Text] [Related]
12. The Tumor Milieu Promotes Functional Human Tumor-Resident Plasmacytoid Dendritic Cells in Humanized Mouse Models.
Maser IP; Hoves S; Bayer C; Heidkamp G; Nimmerjahn F; Eckmann J; Ries CH
Front Immunol; 2020; 11():2082. PubMed ID: 33013879
[TBL] [Abstract] [Full Text] [Related]
13. Corded and Hyalinized Endometrioid Adenocarcinoma (CHEC) of the Uterine Corpus are Characterized by CTNNB1 Mutations and Can Show Adverse clinical outcomes.
Ladwig NR; Umetsu SE; Zaloudek C; Rabban J; Garg K
Int J Gynecol Pathol; 2021 Mar; 40(2):103-115. PubMed ID: 32909971
[TBL] [Abstract] [Full Text] [Related]
14. Live births following fertility preservation using in-vitro maturation of ovarian tissue oocytes.
Segers I; Bardhi E; Mateizel I; Van Moer E; Schots R; Verheyen G; Tournaye H; De Vos M
Hum Reprod; 2020 Sep; 35(9):2026-2036. PubMed ID: 32829388
[TBL] [Abstract] [Full Text] [Related]
15. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
[TBL] [Abstract] [Full Text] [Related]
16. Inflammatory state of lymphatic vessels and miRNA profiles associated with relapse in ovarian cancer patients.
Johnson SC; Chakraborty S; Drosou A; Cunnea P; Tzovaras D; Nixon K; Zawieja DC; Muthuchamy M; Fotopoulou C; Moore JE
PLoS One; 2020; 15(7):e0230092. PubMed ID: 32716937
[TBL] [Abstract] [Full Text] [Related]
17. Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine.
Soyama H; Miyamoto M; Matsuura H; Iwahashi H; Kakimoto S; Ishibashi H; Sakamoto T; Hada T; Suminokura J; Takano M
Cancer Chemother Pharmacol; 2020 May; 85(5):941-947. PubMed ID: 32279102
[TBL] [Abstract] [Full Text] [Related]
18. clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer.
Banys-Paluchowski M; Fehm T; Neubauer H; Paluchowski P; Krawczyk N; Meier-Stiegen F; Wallach C; Kaczerowsky A; Gebauer G
Arch Gynecol Obstet; 2020 Apr; 301(4):1027-1035. PubMed ID: 32144573
[TBL] [Abstract] [Full Text] [Related]
19. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status.
Gallotta V; Bruno M; Conte C; Giudice MT; Davià F; Moro F; Zannoni GF; Fagotti A; De Bonis M; Capoluongo E; Scambia G; Ferrandina G
Eur J Surg Oncol; 2020 Jul; 46(7):1327-1333. PubMed ID: 32085925
[TBL] [Abstract] [Full Text] [Related]
20. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.
León-Castillo A; Gilvazquez E; Nout R; Smit VT; McAlpine JN; McConechy M; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Soslow RA; Ganesan R; Matias-Guiu X; Oliva E; Harrison BT; Church DN; Gilks CB; Bosse T
J Pathol; 2020 Mar; 250(3):312-322. PubMed ID: 31829447
[TBL] [Abstract] [Full Text] [Related]
[Next]
